About deCODE genetics

Headquartered in Reykjavik, Iceland, deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs and diagnostics for common diseases. deCODE is a global leader in gene discovery - our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease.

The company currently has seven lead programs in drug discovery and development, including three in clinical development, and is broadening its pipeline through gene and target discovery work in 50 of the most common diseases. Through its CLIA-registered DNA testing laboratory, deCODE offers deCODE T2™, a novel DNA-based reference laboratory test for the first common and well-validated genetic risk factor for type 2 diabetes, deCODE AF™, whichdetects versions of two SNPs that the company has linked to risk of atrial fibrillation (AF) and deCODE MI™ which detects a genetic or an inherited risk of MI. The company is also developing tests for genetic variants conferring risk of several other common diseases.

deCODE is also leveraging its expertise in human genetics and integrated drug discovery and development capabilities to offer innovative products and services in DNA-based diagnostics, bioinformatics, genotyping, structural biology, drug discovery and clinical development.